Clinical Trial Update: Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating HYP-2090PTSA in patients with KRAS-mutant advanced solid tumors is currently recruiting, focusing on safety/tolerability w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor

Drugs mentioned

• HYP-2090PTSA

Snippet

Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Conditions: Safety, Tolerability | Phase 1, Phase 2 | Status: RECRUITING